Biomarker ID | 1729 |
PMID | 30286759 |
Year | 2018 |
Biomarker | SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in PCa: (PCa: 39.68 ± 30.00; No PCa: 15.04 ± 7.11) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs Normal Adjacent |
Type of Biomarker | Diagnostic |
Cohort | A total of 551 samples were collected, comprising 499 primary prostate cancer samples and 52 normal solid tissue samples. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | RNASeqV2 and Illumina HiSeq 2000 miRNA sequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |